Sanofi and Micromet Collaborate on Early Stage Cancer Antibody
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 11 (Table of Contents)
Published: 6 Nov-2009
DOI: 10.3833/pdr.v2009.i11.1268 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Micromet has licensed out one of its BiTE anticancer antibodies to Sanofi-aventis in a deal that is worth up to US$477 M if all milestones are achieved. Micromet’s BiTE® (Bispecific T Cell Engager) is a novel therapeutic approach for treating cancer.
Copyright: © IQVIA 2018
RSS